ADVERTISEMENT
DESK EN DIRECT·Rédaction marchés mondiaux·Last updated 14s ago
ADVERTISEMENT
Entreprises/RésultatsArticle

ChipMOS Tech earnings beat by $0.16, revenue misses estimates

Semiconductor assembly and test services provider ChipMOS reported adjusted EPS of $1.16, topping forecasts, but revenue fell short of analyst projections amid softer demand.

PA
Priya Anand · Equities & Earnings Desk · 15 Aug 2026 · 1 min de lecture
Partager
ChipMOS Tech earnings beat by $0.16, revenue misses estimates

ChipMOS Technologies Inc. on Thursday reported adjusted earnings per share of $1.16 for the second quarter, exceeding market expectations by $0.16.

Revenue totaled $245.7 million, down 12.3% from the prior-year period and below the consensus estimate of $255 million, according to Refinitiv data. The decline reflected weaker demand across key end markets, including consumer electronics and automotive components.

Gross margin expanded to 24.1% from 21.8% a year earlier, supported by cost efficiencies and improved product mix. Operating income rose 15% year-over-year to $42.3 million, while net income attributable to shareholders increased to $31.2 million from $25.8 million.

Management cited ongoing inventory corrections at major customers as a headwind to top-line growth, though they noted stabilization in orders for high-performance computing and AI-related chips. The company maintained its full-year revenue guidance of $1.05 billion to $1.10 billion, signaling cautious optimism amid macroeconomic uncertainty.

ChipMOS, a leading provider of outsourced semiconductor assembly and test services, operates fabrication facilities in Taiwan and China, serving fabless chip designers and integrated device manufacturers.

Cet article a été produit avec l'assistance de l'IA et édité par un journaliste de Finance Review Daily.
ADVERTISEMENT
Partager cet article
PA
Par
Priya Anand
Equities & Earnings Desk

Priya covers listed equities and corporate earnings, reading quarterly results and guidance for what they signal about sector health and forward valuations.

Plus de Priya Anand →
ADVERTISEMENT
ADVERTISEMENT